Europe
The U.S. Food and Drug Administration (FDA) has a few target action dates scheduled for this week, including one for Sunday, September 23, which was approved in late August.
In September 2016, the U.S. FDA approved Sarepta Therapeutics’ eteplirsen, now marketed as Exondys 51, for Duchenne muscular dystrophy (DMD). And now, two years later, the European Medicines Agency (EMA) has rejected Sarepta’s application for Exondys 51.
TxCell SA today announces financial results for the first half of 2018 and provides an update on the proposed acquisition by Sangamo Therapeutics, Inc.
Guerbet, the global specialist in contrast media and solutions for diagnostic and interventional medical imaging, has announced its presence at the 2018 annual congress of the CIRSE (Cardiovascular & Interventional Radiological Society of Europe), to be held from September 22 to 25, 2018 in Lisbon (Portugal).
Oxurion NV announced today the enrollment of the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME).
Strengthening of NBTXR3 data showing the potential impact on survival in elderly and frail patients with locally advanced head and neck cancers
Domainex Ltd is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018.
Ingenza is pleased to announce that it has become a stakeholder in Amprologix, a spin-out company from the University of Plymouth.
CMS gains exclusive rights to current VAXIMM pipeline and option for future programs for China and other Asian countries, ex-Japan
Two new cleanrooms and a high-end laboratory enable the development and large scale production of electrospun scaffolds that meet the stringent requirements of the Medtech Regenerative Medicine Industry
PRESS RELEASES